Admin Core

管理核心

• 批准号: 10470362
• 负责人: Jean-Pierre J. Issa
• 金额: $ 40.02万
• 依托单位: CORIELL INSTITUTE FOR MEDICAL RESEARCH
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-16 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10470362
• 关键词: Address; Administrator; Advocate; Award; Cancer Prognosis; Clinic; Clinical; Clinical Trials; Collaborations; Communication; Complex; Consultations; Data; Decision Making; Development; Electronic Mail; Eligibility Determination; Ensure; Genomics; Government; Grant; Infrastructure; Institutes; Interdisciplinary Study; Laboratories; Leadership; Malignant Neoplasms; Medical Research; Minority; Monitor; National Cancer Institute; Outcome; Pathology; Patients; Policies; Preparation; Progress Reports; Protocols documentation; Publications; Quality Control; Regulation; Reporting; Research; Research Activity; Research Infrastructure; Research Personnel; Research Project Grants; Resource Sharing; Strategic Planning; Supervision; Therapeutic Studies; Time; Translational Research; United States National Institutes of Health; Woman; Work; base; cancer care; cancer therapy; career; clinical research site; data sharing; design; epigenetic therapy; experience; improved; interdisciplinary collaboration; lectures; meetings; novel; novel therapeutic intervention; programs; quality assurance; recruit; screening; success; symposium; web site

PROJECT SUMMARY The Administrative Core will provide essential support to the Coriell Institute for Medical Research (Coriell) and Van Andel Institute (VAI) Epigenetic Therapy SPORE PIs and investigators to maximize success. It will be co- directed by Drs. Jean-Pierre Issa, Stephen Baylin, and Peter Jones, who co-chair the Executive Committee and provide overall supervision of three Projects, two additional Cores, Developmental Research (DRP) and Career Enhancement (CEP) Programs, and scientific direction of the SPORE. The Core Co-Directors will rely on the extensive broad-based scientific, research, and SPORE experience of the Internal and External Advisory Boards in critical decision making. An oversight committee consisting of the SPORE PIs and three clinical experts from the VAI-SU2C team (Drs. Rudin, El-Khoueiry and O’Connell) will ensure prioritization of SPORE trials within the VAI-SU2C team and at clinical sites. Success of the complex interdisciplinary research in the SPORE depends on integration of diverse epigenetic therapy research approaches. The Core will overcome barriers to interdisciplinary collaboration and data sharing and will ensure a unified translational research effort. The SPORE will be founded on planning, integration, and translational research efforts supported by this Core. Its leadership and staff will be responsible for monitoring/planning scientific activities; providing scientific direction; ensuring emphasis on translational research; ensuring interdisciplinary and inter-SPORE integration with major epigenetic therapy programs within/outside Coriell and VAI and other broad translational research activities; and providing optimal administrative and fiscal management. Specific responsibilities of the Core are: oversee and monitor all SPORE activities; promote integration and communication among the SPORE-related clinical programs; monitor the scientific integrity of all projects, and grant awards; assure compliance with institutional, governmental, and National Cancer Institute regulations; oversee the fiscal and budgetary activities of the SPORE; coordinate data control quality assurance issues; coordinate activities associated with clinical trials, including design of protocols, approval by regulatory bodies, implementation, and eligibility screening and assignment of patients to different studies; provide oversight and support for the shared Resources Cores; coordinate and manage meetings of the SPORE Oversight Committee, Executive Committee, Internal and External Advisory Boards, investigator meetings, research meetings, lectures, and symposia; administer the DRP and the CEP; coordinate interdisciplinary and inter-SPORE interactions and exchanges/meetings with other Epigenetic Therapy SPORE programs and investigators, and other SPORE programs; administer the activities of the Patient Advocates; comply with, and improve policies addressing recruitment and retention of women and minorities; and maintain a Epigenetic Therapy SPORE website focused on issues in epigenetic therapy translational research in cancers.

项目概要 行政核心将为科里尔医学研究所 (Coriell) 和 Van Andel 研究所 (VAI) 表观遗传治疗 SPORE PI 和研究人员最大限度地提高成功率。它将共同 由博士指导。让-皮埃尔·伊萨 (Jean-Pierre Issa)、斯蒂芬·贝林 (Stephen Baylin) 和彼得·琼斯 (Peter Jones) 担任执行委员会联合主席 提供对三个项目、两个附加核心、发展研究 (DRP) 和职业的全面监督 SPORE 的增强 (CEP) 计划和科学方向。核心联合董事将依靠 内部和外部顾问委员会拥有广泛的科学、研究和 SPORE 经验 在关键决策中。由 SPORE PI 和三名临床专家组成的监督委员会 VAI-SU2C 团队（Rudin、El-Khoueiry 和 O’Connell 博士）将确保 SPORE 试验在 VAI-SU2C 团队和临床现场。 SPORE 复杂的跨学科研究的成功取决于 不同表观遗传治疗研究方法的整合。核心将克服障碍 跨学科合作和数据共享，并将确保统一的转化研究工作。孢子 将建立在该核心支持的规划、整合和转化研究工作的基础上。其领导力 工作人员将负责监测/规划科学活动；提供科学指导；确保 重视转化研究；确保跨学科和孢子间与主要表观遗传学的整合 Coriell 和 VAI 内部/外部的治疗计划以及其他广泛的转化研究活动；并提供 优化行政和财政管理。核心的具体职责是：监督和监控所有 孢子活动；促进SPORE相关临床项目之间的整合和交流；监视器 所有项目的科学诚信，并给予奖励；确保遵守机构、政府和 国家癌症研究所法规；监督 SPORE 的财政和预算活动；坐标数据 控制质量保证问题；协调与临床试验相关的活动，包括方案设计， 监管机构的批准、实施、资格筛选以及将患者分配到不同的机构 研究；为共享资源核心提供监督和支持；协调和管理委员会的会议 SPORE 监督委员会、执行委员会、内部和外部顾问委员会、调查员 会议、研究会议、讲座和研讨会；管理 DRP 和 CEP；协调 与其他表观遗传治疗 SPORE 的跨学科和 SPORE 之间的互动和交流/会议 计划和调查员，以及其他 SPORE 计划；管理患者权益倡导者的活动； 遵守并改进有关招聘和保留妇女和少数群体的政策；并维持 表观遗传治疗 SPORE 网站专注于癌症表观遗传治疗转化研究的问题。